Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer | Zendy

Fabrice André | Zendy; Eva Ciruelos | Zendy; Gábor Rubovszky | Zendy; Mario Campone | Zendy; Sibylle Loibl | Zendy; Hope S. Rugo | Zendy; Hiroji Iwata | Zendy; Pierfranco Conté | Zendy; Ingrid A. Mayer | Zendy; Bella Kaufman | Zendy; Toshinari Yamashita | Zendy; YenShen Lu | Zendy; Kenichi Inoue | Zendy; Masato Takahashi | Zendy; Zsuzsanna Pápai | Zendy; Anne-Sophie Longin | Zendy; David Mills | Zendy; Celine Wilke | Zendy; Samit Hirawat | Zendy; Dejan Juric | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Author(s) -

Fabrice André,

Eva Ciruelos,

Gábor Rubovszky,

Mario Campone,

Sibylle Loibl,

Hope S. Rugo,

Hiroji Iwata,

Pierfranco Conté,

Ingrid A. Mayer,

Bella Kaufman,

Toshinari Yamashita,

YenShen Lu,

Kenichi Inoue,

Masato Takahashi,

Zsuzsanna Pápai,

Anne-Sophie Longin,

David Mills,

Celine Wilke,

Samit Hirawat,

Dejan Juric

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1813904

Subject(s) - breast cancer , hormone receptor , hormone , human epidermal growth factor receptor 2 , medicine , cancer research , oncology , receptor , cancer , endocrinology

PIK3CA mutations occur in approximately 40% of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The PI3Kα-specific inhibitor alpelisib has shown antitumor activity in early studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research